Novavax (NVAX) Misses Q2 EPS by $1.12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $10.65 +10.02%
Financial Fact:
Loss from operations: -63.31M
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Loss from operations: -63.31M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Novavax (NASDAQ: NVAX) reported Q2 EPS of ($4.75), $1.12 worse than the analyst estimate of ($3.63). Revenue for the quarter came in at $298 million versus the consensus estimate of $387.87 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Host Hotels & Resorts (HST) Tops Q3 EPS by 1c; offers guidance
- MKS Instruments (MKSI) Tops Q3 EPS by 55c, Beats on Revenue; Offers Q4 Guidance
- Arq, Inc. (ARQ) Misses Q3 EPS by 3c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
